About Kv1.3 Therapeutics

About company

Kv1.3 Therapeutics is a clinical stage biopharmaceutical company focused on advancing new treatment options for rare autoimmune diseases. Their initial focus is on the use of their novel Kv1.3 inhibitor, dalazatide, for the treatment of inclusion body myositis (IBM), a rare, progressively debilitating disease of the muscle.